Theravance Biopharma
TBPH
93 hedge funds and large institutions have $320M invested in Theravance Biopharma in 2014 Q4 according to their latest regulatory filings, with 23 funds opening new positions, 29 increasing their positions, 26 reducing their positions, and 19 closing their positions.
449% more call options, than puts
Call options by funds: $291K | Put options by funds: $53K
21% more first-time investments, than exits
New positions opened: 23 | Existing positions closed: 19
12% more repeat investments, than reductions
Existing positions increased: 29 | Existing positions reduced: 26
2% more funds holding
Funds holding: 91 → 93 (+2)
40% less capital invested
Capital invested by funds: $533M → $320M (-$213M)
100% less funds holding in top 10
Funds holding in top 10: 2 → 0 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RA
Royce & Associates
New York
|
+$8.35M |
| 2 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$7.54M |
| 3 |
CC
Clearline Capital
New York
|
+$4.36M |
| 4 |
First Manhattan
New York
|
+$3.91M |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$3.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IAM
Iridian Asset Management
Westport,
Connecticut
|
-$33.4M |
| 2 |
Capital World Investors
Los Angeles,
California
|
-$16.8M |
| 3 |
First Eagle Investment Management
New York
|
-$10.5M |
| 4 |
PC
Perry Capital
New York
|
-$9.99M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
-$4.78M |
TBPH Hedge Fund Activity: Q4 2014 in Review
93 of the 3,749 institutional investors tracked by Wall St. Rank reported a position in Theravance Biopharma (TBPH) for Q4 2014, worth a combined $320M — down 40% from $533M a quarter earlier.
Buyers outnumbered sellers: 23 funds opened new TBPH positions and 19 closed out — a net gain of 4 holders — while 29 added to existing stakes and 26 trimmed.
The largest buyer was Royce & Associates, adding an estimated $8.35M. The largest seller was Iridian Asset Management, exiting entirely with an estimated $33.4M sold.
- 93 institutional investors held Theravance Biopharma (TBPH) as of Q4 2014, up from 91 in Q3 2014.
- Funds reported $320M of Theravance Biopharma stock for Q4 2014, down 40% quarter-over-quarter.
- 23 funds opened new Theravance Biopharma positions in Q4 2014 and 19 closed out, a net change of +4 holders.
- The largest Theravance Biopharma buyer in Q4 2014 was Royce & Associates, an estimated $8.35M added.
- The largest Theravance Biopharma seller in Q4 2014 was Iridian Asset Management, an estimated $33.4M sold.
Based on aggregated 13F filings for Q4 2014.